Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2.02% is 54% above its 5-year average of -4.38%, around the middle of its 5-year range (-23.89%–9.86%).
As of the fiscal period ended Wednesday, December 31, 2025. 85.20% above its 12-month average of -13.64%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-2.02%
RETURN ON EQUITY (ROE) AVG TTM
-13.64%
RETURN ON EQUITY (ROE) AVG 3Y
-4.29%
RETURN ON EQUITY (ROE) AVG 5Y
-4.38%
RETURN ON EQUITY (ROE) AVG 10Y
-1.37%
RETURN ON EQUITY (ROE) AVG 15Y
7.52%
RETURN ON EQUITY (ROE) AVG 20Y
5.93%
CURRENT VS TTM AVG
+85.20%
CURRENT VS 3Y AVG
+52.91%
CURRENT VS 5Y AVG
+53.86%
CURRENT VS 10Y AVG
-47.66%
CURRENT VS 15Y AVG
-126.87%
CURRENT VS 20Y AVG
-134.08%
SECTOR MEDIAN · HEALTHCARE
10.61%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-119.04%
vs the sector median at left
Viatris Inc.
Market Cap
$20.55B
Return on Equity (ROE)
-2.02%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
Market Cap
$22.03B
Return on Equity (ROE)
20.48%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$18.99B
Return on Equity (ROE)
6.01%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
Market Cap
$22.32B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$22.68B
Return on Equity (ROE)
10.89%
TTM Avg
10.12%
3Y Avg
7.00%
5Y Avg
7.00%
Market Cap
$23.16B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$16.97B
Return on Equity (ROE)
10.37%
TTM Avg
13.30%
3Y Avg
15.60%
5Y Avg
24.66%
Market Cap
$24.28B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$16.41B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $20.55B | -2.02% | -13.64% | -4.29% | -4.38% |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 20.48% | 18.68% | 17.25% | 16.03% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.99B | 6.01% | 6.40% | 5.73% | 4.16% |
| Moderna, Inc. (MRNA)vs › | $22.32B | -46.61% | -32.64% | -13.90% | 0.25% |
| STERIS plc (STE)vs › | $22.68B | 10.89% | 10.12% | 7.00% | 7.00% |
| BioNTech SE (BNTX)vs › | $23.16B | -6.79% | -4.55% | 10.63% | 21.70% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Incyte Corporation (INCY)vs › | $24.28B | 25.41% | 12.92% | 11.29% | 9.83% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.41B | 113.29% | 73.63% | 65.34% | 49.74% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 18.89% | 16.95% | 19.08% | 20.56% |
ROE
-2.0%
ROA
-0.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -23.89% |
| 2024-12-31 | -3.40% |
| 2023-12-31 | 0.27% |
| 2022-12-31 | 9.86% |
| 2021-12-31 | -6.19% |
| 2020-12-31 | -2.92% |
| 2019-12-31 | 0.14% |
| 2018-12-30 | 2.90% |
| 2017-12-30 | 5.23% |
| 2016-12-30 | 4.32% |
| 2015-12-30 | 8.68% |
| 2014-12-30 | 28.55% |
| 2013-12-30 | 21.20% |
| 2012-12-31 | 19.18% |
| 2011-12-31 | 15.37% |
| 2010-12-31 | 9.58% |
| 2009-12-31 | 7.43% |
| 2008-12-31 | -7.11% |
| 2007-12-31 | -44.58% |
| 2006-03-31 | 23.43% |
| 2005-03-31 | 11.03% |
| 2004-03-31 | 20.16% |
